"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Descriptor ID |
D020522
|
| MeSH Number(s) |
C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525
|
| Concept/Terms |
Lymphoma, Mantle-Cell- Lymphoma, Mantle-Cell
- Lymphoma, Mantle Cell
- Lymphomas, Mantle-Cell
- Mantle-Cell Lymphomas
- Lymphocytic Lymphoma, Diffuse, Poorly Differentiated
- Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated
- Mantle-Zone Lymphoma
- Lymphoma, Mantle-Zone
- Lymphomas, Mantle-Zone
- Mantle Zone Lymphoma
- Mantle-Zone Lymphomas
- Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated
- Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated
- Lymphoma, Small-Cell, Centrocytic
- Mantle-Cell Lymphoma
- Mantle Cell Lymphoma
- Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
- Diffuse Lymphocytic Lymphoma, Poorly Differentiated
- Lymphoma, Centrocytic Small-Cell
- Centrocytic Small-Cell Lymphoma
- Centrocytic Small-Cell Lymphomas
- Lymphoma, Centrocytic Small Cell
- Lymphomas, Centrocytic Small-Cell
- Small-Cell Lymphoma, Centrocytic
- Small-Cell Lymphomas, Centrocytic
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".
This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in this website by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 4 | 0 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 2 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 4 | 0 | 4 |
| 2024 | 4 | 0 | 4 |
| 2025 | 3 | 0 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles.
-
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec; 41(12):2323-2338.
-
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood. 2025 Nov 20; 146(21):2544-2560.
-
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma. CPT Pharmacometrics Syst Pharmacol. 2025 Oct; 14(10):1562-1574.
-
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10; 43(20):2285-2295.
-
Pupil sparing oculomotor nerve palsy with concomitant Horner syndrome as a presentation of mantle cell lymphoma relapse. BMJ Case Rep. 2024 Dec 15; 17(12).
-
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States. BMC Cancer. 2024 Aug 13; 24(1):1003.
-
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma. Hematol Oncol. 2024 May; 42(3):e3268.
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
-
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):254-259.
-
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE. Int J Cancer. 2023 09 01; 153(5):1016-1025.